Reply to Drs Ahern and schnoor

摘要

Despite over 50 years of use, currently employed colistin dosing regimens may result in low serum peak concentration leading to suboptimal and delayed effective treatment. A higher single-dose and longer dosing interval strategy, along with a loading dose, as applied in our pilot study, seem effective and less toxic than expected [1].However, we thank Drs Ahern and Schnoor [2] for their safety warning about colistin dosage. We fully agree that while dealing with the issue of dosing strategy, some clarifications are needed in order to avoid under- or over-dosing of colistin.